The Effect of Vitamin B12, Magnesium and Vitamin D in COVID-19 among Geriatric Patients

Introduction: The pandemic hit caused a high prevalence of COVID-19 and fatalities globally. This disease has affected various organ systems and caused systemic inflammation, other than respiratory symptoms. The pathophysiological mechanism also showed that lower levels of vitamin B12 caused disruption in gut microbiota and increased oxidative stress. Reduced levels of vitamins and magnesium, which resulted from the infection of this disease, have led to further deterioration of the health status. Aims and Objectives: This study is intended to evaluate the effect of combination therapy of vitamin D, magnesium, and vitamin B12 in COVID-19 patients by analyzing the outcomes of the disease when this combination therapy is applied. Materials and Methods: This current study is a cohort observational prospective, in which 30 patients were given a combination of cholecalciferol (vitamin D3) of 1000 IU, magnesium oxide at 150 mg dose and methylcobalamin (Vitamin B12) of 500 µg, referred to as Intervention group. Another 25 patients were taken for comparison and referred to as the Control group. The baseline data was collected and the outcomes were observed and compared between the two groups. Results: The study also found that the duration required to run the management of COVID-19 is significantly less in the Intervention group than the control group (p<0.05). The study further added that the group which received the combination therapy required less oxygen therapy with or without ICU support (p<0.05). Conclusion: The study concluded that this combination therapy can improve the health status of COVID-19 patients by decreasing the probability to require oxygen therapy and ICU support. The study also concluded that this combined therapy can reduce the duration of hospitalization of COVID-19 patients.